guidelines:
  1: Risk_Score_Asthma_Exacerbation.v1
test_cases:
- id: RSE Score 91-100
  input:
    1:
      gt0003|Body Mass Index: 31,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 13|local::at0008|≥2.5  +13|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 20|local::at0012|<80%  +20|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 27|local::at0019|Yes  +27|
      gt0007|Rescue inhaler usage per day: 26|local::at0016|≥4  +26|
  expected_output:
    1:
      gt0011|RSE Score: 100
      gt0010|BMI ≥30 kg/m²: 14|local::at0004|Yes +14|
      gt0012|Likelihood of exacerbation in 6 months: 37-45%
- id: RSE Score 81-90
  input:
    1:
      gt0003|Body Mass Index: 31,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 20|local::at0012|<80%  +20|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 27|local::at0019|Yes  +27|
      gt0007|Rescue inhaler usage per day: 26|local::at0016|≥4  +26|
  expected_output:
    1:
      gt0011|RSE Score: 87
      gt0010|BMI ≥30 kg/m²: 14|local::at0004|Yes +14|
      gt0012|Likelihood of exacerbation in 6 months: 30-37%
- id: RSE Score 71-80
  input:
    1:
      gt0003|Body Mass Index: 31,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 20|local::at0012|<80%  +20|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 27|local::at0019|Yes  +27|
      gt0007|Rescue inhaler usage per day: 11|local::at0015|2-4  +11|
  expected_output:
    1:
      gt0011|RSE Score: 72
      gt0010|BMI ≥30 kg/m²: 14|local::at0004|Yes +14|
      gt0012|Likelihood of exacerbation in 6 months: 24-30%
- id: RSE Score 61-70
  input:
    1:
      gt0003|Body Mass Index: 31,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 20|local::at0012|<80%  +20|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 27|local::at0019|Yes  +27|
      gt0007|Rescue inhaler usage per day: 0|local::at0014|<2  +0|
  expected_output:
    1:
      gt0011|RSE Score: 61
      gt0010|BMI ≥30 kg/m²: 14|local::at0004|Yes +14|
      gt0012|Likelihood of exacerbation in 6 months: 18-24%
- id: RSE Score 51-60
  input:
    1:
      gt0003|Body Mass Index: 31,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 13|local::at0011|80% to 90%  +13|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 27|local::at0019|Yes  +27|
      gt0007|Rescue inhaler usage per day: 0|local::at0014|<2  +0|
  expected_output:
    1:
      gt0011|RSE Score: 54
      gt0010|BMI ≥30 kg/m²: 14|local::at0004|Yes +14|
      gt0012|Likelihood of exacerbation in 6 months: 15-18%
- id: RSE Score 41-50
  input:
    1:
      gt0003|Body Mass Index: 31,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 20|local::at0012|<80%  +20|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 0|local::at0018|No  +0|
      gt0007|Rescue inhaler usage per day: 11|local::at0015|2-4  +11|
  expected_output:
    1:
      gt0011|RSE Score: 45
      gt0010|BMI ≥30 kg/m²: 14|local::at0004|Yes +14|
      gt0012|Likelihood of exacerbation in 6 months: 12-15%
- id: RSE Score 31-40
  input:
    1:
      gt0003|Body Mass Index: 31,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 13|local::at0011|80% to 90%  +13|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 0|local::at0018|No  +0|
      gt0007|Rescue inhaler usage per day: 11|local::at0015|2-4  +11|
  expected_output:
    1:
      gt0011|RSE Score: 38
      gt0010|BMI ≥30 kg/m²: 14|local::at0004|Yes +14|
      gt0012|Likelihood of exacerbation in 6 months: 10-12%
- id: RSE Score 21-30
  input:
    1:
      gt0003|Body Mass Index: 31,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 0|local::at0010|≥90%  +0|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 0|local::at0018|No  +0|
      gt0007|Rescue inhaler usage per day: 11|local::at0015|2-4  +11|
  expected_output:
    1:
      gt0011|RSE Score: 25
      gt0010|BMI ≥30 kg/m²: 14|local::at0004|Yes +14|
      gt0012|Likelihood of exacerbation in 6 months: 7-10%
- id: RSE Score 11-20
  input:
    1:
      gt0003|Body Mass Index: 25,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 0|local::at0010|≥90%  +0|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 0|local::at0018|No  +0|
      gt0007|Rescue inhaler usage per day: 11|local::at0015|2-4  +11|
  expected_output:
    1:
      gt0011|RSE Score: 11
      gt0010|BMI ≥30 kg/m²: 0|local::at0003|No +0|
      gt0012|Likelihood of exacerbation in 6 months: 5-7%
- id: RSE Score 0-10
  input:
    1:
      gt0003|Body Mass Index: 25,kg/m2
      gt0005|Asthma Control Questionnaire-5 (ACQ-5) Score: 0|local::at0006|<1.5  +0|
      gt0006|Postbronchodilator FEV1 (% Predicted normal value): 0|local::at0010|≥90%  +0|
      gt0008|Global Initiative for Asthma (GINA) treatment step 4 or higher. Medium-high inhaled steroid/long acting beta agonist.: 0|local::at0018|No  +0|
      gt0007|Rescue inhaler usage per day: 0|local::at0014|<2  +0|
  expected_output:
    1:
      gt0011|RSE Score: 0
      gt0010|BMI ≥30 kg/m²: 0|local::at0003|No +0|
      gt0012|Likelihood of exacerbation in 6 months: 5%
